<DOC>
	<DOCNO>NCT00004492</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare efficacy hydroxyurea without clotrimazole term limit severity anemia rate hemolysis patient sickle cell anemia .</brief_summary>
	<brief_title>Phase I/II Randomized Study Hydroxyurea With Without Clotrimazole Patients With Sickle Cell Anemia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Patients randomize one two treatment arm . Arm I : Patients receive oral hydroxyurea oral clotrimazole daily 12 month . Arm II : Patients receive oral hydroxyurea daily 12 month . Patients follow 6 week . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis sickle cell anemia confirm hemoglobin electrophoresis Received hydroxyurea least 6 month On stable dose least 3 month Tolerating dose least 5 mg/kg/day Prior/Concurrent Therapy Chemotherapy : No concurrent antisickling agent Other : No concurrent drug may interact influence metabolism hydroxyurea clotrimazole Patient Characteristics Hematopoietic : WBC least 4000/mm3 Platelet count least 150,000/mm3 Hemoglobin less 11 g/dL Hepatic : AST/ALT great 100 units/L Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No prior adverse reaction hydroxyurea clotrimazole No recent progressive neurologic dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>sickle cell anemia</keyword>
</DOC>